;PMID: 4052099
;source_file_1885.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..174] = [t:50..174]
;2)section:[e:178..199] = [t:178..199]
;3)sentence:[e:203..420] = [t:203..420]
;4)sentence:[e:421..555] = [t:421..555]
;5)sentence:[e:556..706] = [t:556..706]
;6)sentence:[e:707..864] = [t:707..864]
;7)sentence:[e:865..1043] = [t:865..1043]
;8)sentence:[e:1044..1125] = [t:1044..1125]
;9)sentence:[e:1126..1207] = [t:1126..1207]
;10)sentence:[e:1208..1327] = [t:1208..1327]
;11)sentence:[e:1328..1428] = [t:1328..1428]
;12)sentence:[e:1429..1602] = [t:1429..1602]
;13)section:[e:1606..1650] = [t:1606..1650]

;section 0 Span:0..44
;Biochem Pharmacol. 1985 Oct 1;34(19):3571-5.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1985) (NNP:[24..27] Oct) (CC:[28..33] 1;34-LRB-)
        (CD:[33..35] 19) (-RRB-:[35..36] -RRB-) (::[36..37] :)
        (CD:[37..41] 3571) (CD:[41..43] -5) (.:[43..44] .)))

;sentence 1 Span:50..174
;Phase 1 and Phase 2 drug metabolism in isolated epidermal cells from adult 
;hairless mice and in whole human hair follicles.
;[70..74]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP
        (NML (NN:[50..55] Phase) (CD:[56..57] 1))
        (NML-1 (-NONE-:[57..57] *P*)))
      (CC:[58..61] and)
      (NP
        (NML (NN:[62..67] Phase) (CD:[68..69] 2))
        (NML-1 (NN:[70..74] drug) (NN:[75..85] metabolism))))
    (PP-LOC
      (PP (IN:[86..88] in)
        (NP
          (NP (VBN:[89..97] isolated) (JJ:[98..107] epidermal)
              (NNS:[108..113] cells))
          (NP (IN:[114..118] from)
            (NP (JJ:[119..124] adult) (JJ:[126..134] hairless)
                (NNS:[135..139] mice)))))
      (CC:[140..143] and)
      (PP (IN:[144..146] in)
        (NP (JJ:[147..152] whole) (JJ:[153..158] human) (NN:[159..163] hair)
            (NNS:[164..173] follicles))))
    (.:[173..174] .)))

;section 2 Span:178..199
;Finnen MJ, Shuster S.
(SEC
  (FRAG (NNP:[178..184] Finnen) (NNP:[185..187] MJ) (,:[187..188] ,)
        (NNP:[189..196] Shuster) (NNP:[197..199] S.)))

;sentence 3 Span:203..420
;A sensitive fluorimetric assay to determine both Phase 1 (oxidation) and
;Phase 2  (conjugation) drug metabolism in epidermal cells isolated from
;hairless mice,  using ethoxycoumarin as a model substrate, is described.
;[299..303]:substance:"drug"
;[370..384]:substance:"ethoxycoumarin"
;[396..405]:substance:"substrate"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[203..204] A) (JJ:[205..214] sensitive)
          (JJ:[215..227] fluorimetric) (NN:[228..233] assay))
      (SBAR
        (WHNP-3 (-NONE-:[233..233] 0))
        (S
          (NP-SBJ-3 (-NONE-:[233..233] *))
          (VP (TO:[234..236] to)
            (VP (VB:[237..246] determine)
              (NP (CC:[247..251] both)
                (NP
                  (NML
                    (NML (NN:[252..257] Phase) (CD:[258..259] 1))
                    (NML (-LRB-:[260..261] -LRB-) (NN:[261..270] oxidation)
                         (-RRB-:[270..271] -RRB-)))
                  (NML-1 (-NONE-:[271..271] *P*)))
                (CC:[272..275] and)
                (NP
                  (NML
                    (NML (NN:[276..281] Phase) (CD:[282..283] 2))
                    (NML (-LRB-:[285..286] -LRB-) (NN:[286..297] conjugation)
                         (-RRB-:[297..298] -RRB-)))
                  (NML-1 (NN:[299..303] drug) (NN:[304..314] metabolism))))
              (PP-LOC (IN:[315..317] in)
                (NP
                  (NP (JJ:[318..327] epidermal) (NNS:[328..333] cells))
                  (VP (VBN:[334..342] isolated)
                    (NP (-NONE-:[342..342] *))
                    (PP (IN:[343..347] from)
                      (NP (JJ:[348..356] hairless) (NNS:[357..361] mice))))))
              (,:[361..362] ,)
              (S-MNR
                (NP-SBJ (-NONE-:[362..362] *))
                (VP (VBG:[364..369] using)
                  (NP (NN:[370..384] ethoxycoumarin))
                  (PP (IN:[385..387] as)
                    (NP (DT:[388..389] a) (NN:[390..395] model)
                        (NN:[396..405] substrate))))))))))
    (,:[405..406] ,)
    (VP (VBZ:[407..409] is)
      (VP (VBN:[410..419] described)
        (NP-2 (-NONE-:[419..419] *))))
    (.:[419..420] .)))

;sentence 4 Span:421..555
;Ethoxycoumarin was  metabolized by isolated epidermal cells via dealkylation
;to 7-hydroxycoumarin  (7-OHC) and subsequent conjugation.
;[421..435]:substance:"Ethoxycoumarin"
;[501..518]:substance:"7-hydroxycoumarin"
;[521..526]:substance:"7-OHC"
(SENT
  (S
    (NP-SBJ-1 (NN:[421..435] Ethoxycoumarin))
    (VP (VBD:[436..439] was)
      (VP (VBN:[441..452] metabolized)
        (NP-1 (-NONE-:[452..452] *))
        (PP (IN:[453..455] by)
          (NP-LGS (VBN:[456..464] isolated) (JJ:[465..474] epidermal)
                  (NNS:[475..480] cells)))
        (PP-MNR (IN:[481..484] via)
          (NP
            (NP
              (NP (NN:[485..497] dealkylation))
              (PP (TO:[498..500] to)
                (NP
                  (NP (NN:[501..518] 7-hydroxycoumarin))
                  (NP (-LRB-:[520..521] -LRB-) (NN:[521..526] 7-OHC)
                      (-RRB-:[526..527] -RRB-)))))
            (CC:[528..531] and)
            (NP (JJ:[532..542] subsequent) (NN:[543..554] conjugation))))))
    (.:[554..555] .)))

;sentence 5 Span:556..706
;Phase 1 metabolites were extracted in ether  from the aqueous incubation
;media, back extracted into sodium hydroxide and  determined
;fluorimetrically.
;[564..575]:substance:"metabolites"
;[594..599]:substance:"ether"
;[629..634]:substance:"media"
;[656..672]:substance:"sodium hydroxide"
(SENT
  (S
    (NP-SBJ-1
      (NML (NN:[556..561] Phase) (CD:[562..563] 1))
      (NNS:[564..575] metabolites))
    (VP (VBD:[576..580] were)
      (VP
        (VP (VBN:[581..590] extracted)
          (NP-1 (-NONE-:[590..590] *))
          (NP (IN:[591..593] in)
            (NP (NN:[594..599] ether)))
          (PP (IN:[601..605] from)
            (NP (DT:[606..609] the) (JJ:[610..617] aqueous)
                (NN:[618..628] incubation) (NN:[629..634] media))))
        (,:[634..635] ,)
        (VP (RB:[636..640] back) (VBN:[641..650] extracted)
          (NP-1 (-NONE-:[650..650] *))
          (PP (IN:[651..655] into)
            (NP (NN:[656..662] sodium) (NN:[663..672] hydroxide))))
        (CC:[673..676] and)
        (VP (VBN:[678..688] determined)
          (NP-1 (-NONE-:[688..688] *))
          (ADVP-MNR (RB:[689..705] fluorimetrically)))))
    (.:[705..706] .)))

;sentence 6 Span:707..864
;Conjugated metabolites remaining in the aqueous  phase were hydrolysed by the
;action of beta-glucuronidase and extracted and  determined in a similar
;manner.
;[718..729]:substance:"metabolites"
;[795..813]:substance:"beta-glucuronidase"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBN:[707..717] Conjugated) (NNS:[718..729] metabolites))
      (VP (VBG:[730..739] remaining)
        (PP (IN:[740..742] in)
          (NP (DT:[743..746] the) (JJ:[747..754] aqueous) (NN:[756..761] phase)))))
    (VP (VBD:[762..766] were)
      (VP
        (VP (VBN:[767..777] hydrolysed)
          (NP-1 (-NONE-:[777..777] *))
          (PP-MNR (IN:[778..780] by)
            (NP
              (NP (DT:[781..784] the) (NN:[785..791] action))
              (PP (IN:[792..794] of)
                (NP (NN:[795..813] beta-glucuronidase))))))
        (CC:[814..817] and)
        (VP (VBN:[818..827] extracted) (CC:[828..831] and)
            (VBN:[833..843] determined)
          (NP-1 (-NONE-:[843..843] *))
          (PP-MNR (IN:[844..846] in)
            (NP (DT:[847..848] a) (JJ:[849..856] similar) (NN:[857..863] manner))))))
    (.:[863..864] .)))

;sentence 7 Span:865..1043
;The production of free 7-OHC by isolated  epidermal cells was biphasic at all
;substrate concentrations tested, exhibiting  an initial linear increase
;followed by a plateau phase.
;[888..893]:substance:"7-OHC"
;[943..952]:substance:"substrate"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[865..868] The) (NN:[869..879] production))
      (PP (IN:[880..882] of)
        (NP (JJ:[883..887] free) (NN:[888..893] 7-OHC)))
      (PP (IN:[894..896] by)
        (NP (VBN:[897..905] isolated) (JJ:[907..916] epidermal)
            (NNS:[917..922] cells))))
    (VP (VBD:[923..926] was)
      (ADJP-PRD (JJ:[927..935] biphasic))
      (PP (IN:[936..938] at)
        (NP
          (NP (DT:[939..942] all) (NN:[943..952] substrate)
              (NNS:[953..967] concentrations))
          (VP (VBN:[968..974] tested)
            (NP (-NONE-:[974..974] *)))))
      (,:[974..975] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[975..975] *))
        (VP (VBG:[976..986] exhibiting)
          (NP
            (NP (DT:[988..990] an) (JJ:[991..998] initial)
                (JJ:[999..1005] linear) (NN:[1006..1014] increase))
            (VP (VBN:[1015..1023] followed)
              (NP (-NONE-:[1023..1023] *))
              (PP (IN:[1024..1026] by)
                (NP-LGS (DT:[1027..1028] a) (NN:[1029..1036] plateau)
                        (NN:[1037..1042] phase))))))))
    (.:[1042..1043] .)))

;sentence 8 Span:1044..1125
;The plateau phase was  attributable to the conjugation of 7-OHC produced in
;situ.
;[1102..1107]:substance:"7-OHC"
(SENT
  (S
    (NP-SBJ (DT:[1044..1047] The) (NN:[1048..1055] plateau)
            (NN:[1056..1061] phase))
    (VP (VBD:[1062..1065] was)
      (ADJP-PRD (JJ:[1067..1079] attributable)
        (PP (TO:[1080..1082] to)
          (NP
            (NP (DT:[1083..1086] the) (NN:[1087..1098] conjugation))
            (PP (IN:[1099..1101] of)
              (NP
                (NP (NN:[1102..1107] 7-OHC))
                (VP (VBN:[1108..1116] produced)
                  (NP (-NONE-:[1116..1116] *))
                  (ADVP (FW:[1117..1119] in) (FW:[1120..1124] situ)))))))))
    (.:[1124..1125] .)))

;sentence 9 Span:1126..1207
;Metabolism was  inhibited by SKF 525A, carbon monoxide, and
;alpha-naphthoflavone.
;[1155..1163]:substance:"SKF 525A"
;[1165..1180]:substance:"carbon monoxide"
;[1186..1206]:substance:"alpha-naphthoflavone"
(SENT
  (S
    (NP-SBJ-1 (NN:[1126..1136] Metabolism))
    (VP (VBD:[1137..1140] was)
      (VP (VBN:[1142..1151] inhibited)
        (NP-1 (-NONE-:[1151..1151] *))
        (PP (IN:[1152..1154] by)
          (NP-LGS
            (NP (NN:[1155..1158] SKF) (NN:[1159..1163] 525A))
            (,:[1163..1164] ,)
            (NP (NN:[1165..1171] carbon) (NN:[1172..1180] monoxide))
            (,:[1180..1181] ,) (CC:[1182..1185] and)
            (NP (NN:[1186..1206] alpha-naphthoflavone))))))
    (.:[1206..1207] .)))

;sentence 10 Span:1208..1327
;Endogenous  supplies of reducing equivalents in the form of NADPH were
;adequate to attain  maximal rates of metabolism.
;[1268..1273]:substance:"NADPH"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1208..1218] Endogenous) (NNS:[1220..1228] supplies))
      (PP (IN:[1229..1231] of)
        (NP
          (NP (VBG:[1232..1240] reducing) (NNS:[1241..1252] equivalents))
          (PP (IN:[1253..1255] in)
            (NP
              (NP (DT:[1256..1259] the) (NN:[1260..1264] form))
              (PP (IN:[1265..1267] of)
                (NP (NN:[1268..1273] NADPH))))))))
    (VP (VBD:[1274..1278] were)
      (ADJP-PRD (JJ:[1279..1287] adequate))
      (S-PRP
        (NP-SBJ (-NONE-:[1287..1287] *))
        (VP (TO:[1288..1290] to)
          (VP (VB:[1291..1297] attain)
            (NP
              (NP (JJ:[1299..1306] maximal) (NNS:[1307..1312] rates))
              (PP (IN:[1313..1315] of)
                (NP (NN:[1316..1326] metabolism))))))))
    (.:[1326..1327] .)))

;sentence 11 Span:1328..1428
;With human hair follicles both Phase 1 and Phase 2  activity was detectable
;in 7 out of 11 subjects.
(SENT
  (S
    (PP (IN:[1328..1332] With)
      (NP (JJ:[1333..1338] human) (NN:[1339..1343] hair)
          (NNS:[1344..1353] follicles)))
    (NP-SBJ (CC:[1354..1358] both)
      (NP
        (NML (NN:[1359..1364] Phase) (CD:[1365..1366] 1))
        (NML-1 (-NONE-:[1366..1366] *P*)))
      (CC:[1367..1370] and)
      (NP
        (NML (NN:[1371..1376] Phase) (CD:[1377..1378] 2))
        (NML-1 (NN:[1380..1388] activity))))
    (VP (VBD:[1389..1392] was)
      (ADJP-PRD (JJ:[1393..1403] detectable))
      (PP-LOC (IN:[1404..1406] in)
        (NP
          (NP (CD:[1407..1408] 7))
          (PP (IN:[1409..1412] out)
            (PP (IN:[1413..1415] of)
              (NP (CD:[1416..1418] 11) (NNS:[1419..1427] subjects)))))))
    (.:[1427..1428] .)))

;sentence 12 Span:1429..1602
;The assay has the advantages of  being sensitive, producing single defined
;metabolites from both Phase 1 and  Phase 2 metabolism; is readily adaptable
;to human skin samples.
;[1504..1515]:substance:"metabolites"
(SENT
  (S
    (NP-SBJ (DT:[1429..1432] The) (NN:[1433..1438] assay))
    (VP
      (VP (VBZ:[1439..1442] has)
        (NP
          (NP (DT:[1443..1446] the) (NNS:[1447..1457] advantages))
          (PP (IN:[1458..1460] of)
            (S-NOM
              (S
                (NP-SBJ (-NONE-:[1460..1460] *))
                (VP (VBG:[1462..1467] being)
                  (ADJP-PRD (JJ:[1468..1477] sensitive))))
              (,:[1477..1478] ,)
              (S
                (NP-SBJ (-NONE-:[1478..1478] *))
                (VP (VBG:[1479..1488] producing)
                  (NP
                    (NP (JJ:[1489..1495] single) (VBN:[1496..1503] defined)
                        (NNS:[1504..1515] metabolites))
                    (PP (IN:[1516..1520] from)
                      (NP (CC:[1521..1525] both)
                        (NP
                          (NML (NN:[1526..1531] Phase) (CD:[1532..1533] 1))
                          (NML-1 (-NONE-:[1533..1533] *P*)))
                        (CC:[1534..1537] and)
                        (NP
                          (NML (NN:[1539..1544] Phase) (CD:[1545..1546] 2))
                          (NML-1 (NN:[1547..1557] metabolism))))))))))))
      (::[1557..1558] ;)
      (VP (VBZ:[1559..1561] is)
        (ADJP-PRD (RB:[1562..1569] readily) (JJ:[1570..1579] adaptable)
          (PP (TO:[1580..1582] to)
            (NP (JJ:[1583..1588] human) (NN:[1589..1593] skin)
                (NNS:[1594..1601] samples))))))
    (.:[1601..1602] .)))

;section 13 Span:1606..1650
;PMID: 4052099 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1606..1610] PMID) (::[1610..1611] :) (CD:[1612..1619] 4052099)
        (NN:[1620..1621] -LSB-) (NNP:[1621..1627] PubMed) (::[1628..1629] -)
        (NN:[1630..1637] indexed) (IN:[1638..1641] for)
        (NNP:[1642..1650] MEDLINE-RSB-)))
